Anti-proliferative effect of Cinobufagin on acute myeloid leukemia cells with repression of c-Myc pathway associated genes (RNA-Seq)
Ontology highlight
ABSTRACT:
ORGANISM(S): Homo sapiens
PROVIDER: GSE190996 | GEO | 2022/12/09
REPOSITORIES: GEO
Similar Datasets
Project description:To analyse the effect of Cinobufagin to human acute myeloid leukemia cell lines, HL60 and Kasumi-1.
2022-12-09 | GSE190995 | GEO
Project description:This SuperSeries is composed of the SubSeries listed below.
2022-12-09 | GSE190997 | GEO
Project description:Cinobufagin, belonged to a kind of cardiotonic steroids (CSs), derived from the extracts of toad venom, which presented the significant anticancer properties as inhibitors of Na+/K+-ATPase (NKA) in many cancer cells. Nowadays, cinobufagin was usually used to apply for clinical treatments of patients in advanced stage of cancer, and improved their quality of life and prolonged their survival period. Unfortunately, long-term drug treatment had also led to multi-drug-resistance (MDR) likely other chemotherapy drugs. However, this detailed mechanism was not still clear. In the present study, we noticed that cinobufagin could trigger the protective autophagy to suppress cells apoptosis in liver cancer HepG2 and Huh-7 cells by inhibition of PI3K-AKT-mTOR pathway using RNA-seq method. We also confirmed that cinobufagin could inhibit cells proliferation and induce cells apoptosis, and generated cells autophagy by up-regulation expression of LC3B-II, Beclin 1 and Atg12-atg5. More importantly, autophagy inhibitor (MRT68921) enhances the anti-proliferation and pro-apoptosis effects of cinobufagin in HCC cells. Therefore, we thought that a combination of cinobufagin and autophagy inhibitors may be a potential effective strategy in treatment of HCC.
2019-12-26 | GSE142588 | GEO
Project description:This study investigates the alterations in the transcriptomic landscape of cells following treatment with cinobufagin.
2024-09-10 | GSE276415 | GEO
Project description:Osteoarthritis is the most common degenerative disorder of the modern world. However, many basic cellular features and molecular processes of the disease are poorly understood. In the present study we used oligonucleotide-based microarray analysis of genes of known or assumed relevance to the cellular phenotype to screen for relevant differences in gene expression between normal and osteoarthritic chondrocytes. Custom made oligonucleotide DNA arrays were used to screen for differentially expressed genes in normal (n = 9) and osteoarthritic (n = 10) cartilage samples. Real-time polymerase chain reaction (PCR) with gene-specific primers was used for quantification. Primary human adult articular chondrocytes and chondrosarcoma cell line HCS-2/8 were used to study changes in gene expression levels after stimulation with interleukin-1beta and bone morphogenetic protein, as well as the dependence on cell differentiation. In situ hybridization with a gene-specific probe was applied to detect mRNA expression levels in fetal growth plate cartilage. Overall, more than 200 significantly regulated genes were detected between normal and osteoarthritic cartilage (P < 0.01). One of the significantly repressed genes, Tob1, encodes a protein belonging to a family involved in silencing cells in terms of proliferation and functional activity. The repression of Tob1 was confirmed by quantitative PCR and correlated to markers of chondrocyte activity and proliferation in vivo. Tob1 expression was also detected at a decreased level in isolated chondrocytes and in the chondrosarcoma cell line HCS-2/8. Again, in these cells it was negatively correlated with proliferative activity and positively with cellular differentiation. Altogether, the downregulation of the expression of Tob1 in osteoarthritic chondrocytes might be an important aspect of the cellular processes taking place during osteoarthritic cartilage degeneration. Activation, the reinitiation of proliferative activity and the loss of a stable phenotype are three major changes in osteoarthritic chondrocytes that are highly significantly correlated with the repression of Tob1 expression.
| S-EPMC1065318 | biostudies-literature
Project description:RNA-seq in liver cancer cell and cinobufagin treatment cells
| PRJNA597601 | ENA
Project description:Analysis of technical variance of ChIP-on-Chip studies by characterization of Myc-binding in HL60 cells. Keywords: Chip-on-chip Characterization of c-Myc binding in HL60 cells. Thirteen biologically independent replicates of growing HL60 cells were subjected to ChIP with an N-terminal c-Myc antibody and hybridized to CpG island microarrays
2010-05-17 | E-GEOD-8447 | biostudies-arrayexpress
Project description:The transcription factor ZNF224 plays a key proapoptotic role in chronic myelogenous leukemia (CML), by modulating Wilms Tumor protein 1 (WT1) dependent apoptotic genes transcription. Recently, we demonstrated that Bcr-Abl signaling represses ZNF224 expression in Bcr-Abl positive CML cell lines and in CML patients. Interestingly, Imatinib and second-generation tyrosine kinase inhibitors specifically increase ZNF224 expression. On the other hand, Bcr-Abl positively modulates, via JAK2 activation, the expression of the c-Myc oncogene, which is required for Bcr-Abl oncogenic transformation in CML. Consequently, JAK2 inhibitors represent promising molecular therapeutic tools in CML. In this work, we demonstrate that ZNF224 is a novel transcriptional repressor of c-Myc in CML. We also show that ZNF224 induction by Imatinib and AG490, a specific JAK2 inhibitor, is responsible for the transcriptional repression of c-MYC, thus highlighting the crucial role of the ZNF224/c-Myc axis in Imatinib responsiveness. Interestingly, we also report that ZNF224 is induced by AG490 in Imatinib-resistant CML cells, leading to c-Myc repression and apoptosis induction. These findings suggest that the development of molecular tools able to induce ZNF224 expression could provide promising means to bypass Imatinib resistance in CML.
| S-EPMC5790473 | biostudies-literature
Project description:Acute myeloid leukemia (AML) is a clonal hematopoietic malignancy, characterized by expansion of immature leukemic blasts in the bone marrow. In AML, specific tyrosine kinases have been implicated in leukemogenesis, and are associated with poor treatment outcome. However, targeted therapy using kinase inhibitors (KIs) has had limited success, and may be improved by proper patient selection. We performed phosphotyrosine (pY) based, label-free phosphoproteomics to identify hyperphosphorylated, active kinases in AML cell lines as targets and predictive biomarkers to select KIs for treatment. We identified 3605 class I phosphorylation sites in 16 AML cell lines (EOL-1, KG-1a, MM6, KG-1, ME-1, NB-4, Kasumi-3, MV4-11, THP-1, HEL, HL-60, Kasumi-1, Kasumi-6, ML-2, OCI-AML3, MOLM-13) that exhibited large variation in the number and level of phosphopeptides per cell line (241-2764). Ranking analyses successfully pinpointed the hyperactive kinases PDGFRA, FGFR1, KIT, and FLT3 in eight cell lines with a corresponding kinase mutation. Additionally, we identified unexpected drivers in two more cell lines (PDGFRA in Kasumi-3 and FLT3 in MM6) which proved sensitive to specific kinase inhibitors. Six cell lines without a clear receptor tyrosine kinase (RTK) driver showed evidence of MAPK1/3 activation, consistent with the presence of activating RAS mutations. Our data show the potential of pY phosphoproteomics to identify key drivers in AML cells, and the predictive value of the phosphoproteome profiles in TKi selection for targeted treatment.
2019-11-11 | PXD007237 | Pride
Project description:N6-Methyladenosine (m6A) is the most abundant post-transcriptional modification in eukaryotes, the imbalance of which is reported to be associated with various pathological processes, including drug resistance. In this study, we analyzed the methylated RNA immunoprecipitation combined with next-generation sequencing (MeRIP-seq) data of AML cell line HL60 and its adriamycin-resistant cell line HL60/ADR. We found a total of 40550 peaks, representing 15640 genes in HL60, and a total of 38834 peaks, representing 15285 genes in HL60/ADR. A total of 4437 differentially methylated m6A peaks within 3461 genes have been found between HL60 and HL60/ADR. Among them, 3587 differentially m6A peaks within 2790 genes were hyper-methylated, and 850 m6A peaks within 671 genes were hypo-methylated. KEGG pathway analysis showed that pathways were enriched in tumor and drug-resistant related signaling pathway. Results of MeRIP-seq showed that fold enrichment of global m6A peaks was higher in HL60/ADR compared to HL60. This study provides a framework for the application of comprehensive mRNA m6A profiling towards acute myeloid leukemia cell line (HL60) and its adriamycin-resistant acute myeloid leukemia cell line (HL60/ADR).
2021-12-29 | GSE192618 | GEO